title: HSV excretion after bone marrow transplantation: a 4-year survey.
abstract: BACKGROUND
  Herpes simplex virus (HSV) oral excretions are common after bone marrow transplantation (BMT).
  
  
  OBJECTIVE
  We report a 4-year systematic survey of HSV excretions in an adult population who underwent BMT (289 transplantations).
  
  
  METHODS
  Patients received either intravenous ACV treatment when mucositis occurred or systematic intravenous ACV prophylaxis from initiation of the BMT conditioning until the end of aplasia. All patients were followed up for HSV excretions.
  
  
  RESULTS
  Twenty-eight patients (9.7%) excreted HSV. The occurrence of HSV excretions was similar in both allogeneic and autologous transplant patients. The incidence was significantly lower when ACV was systematically used after transplantation (2.5%) compared to when ACV was implemented for mucositis (12%). ACV-resistant HSV was detected in three patients who received allogeneic transplantation, representing 27% of allogeneic recipients excreting HSV.
  
  
  CONCLUSIONS
  HSV infection prophylaxis with high dose of intravenous ACV resulted in a decreased incidence of HSV excretion. Nevertheless, the risk of emergence of ACV resistance, especially among allogeneic transplant patients, appears to be identical whatever the route and dose of ACV prophylaxis.
authors.affiliation: Laboratory of Virology of the Hospices Civils de Lyon, Domaine Rockefeller, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France. fmorfin@rockefeller.univ-lyon1.fr
authors.forename: Florence
authors.initials: F
authors.lastname: Morfin
authors.forename: Karin
authors.initials: K
authors.lastname: Bilger
authors.forename: Anne
authors.initials: A
authors.lastname: Boucher
authors.forename: Anne
authors.initials: A
authors.lastname: Thiebaut
authors.forename: Fatiha
authors.initials: F
authors.lastname: Najioullah
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bleyzac
authors.forename: Nicole
authors.initials: N
authors.lastname: Raus
authors.forename: Sylvie
authors.initials: S
authors.lastname: Bosshard
authors.forename: Michèle
authors.initials: M
authors.lastname: Aymard
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Danielle
authors.initials: D
authors.lastname: Thouvenot
mesh_terms: D000212:Acyclovir / Q000494:pharmacology / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D024882:Drug Resistance, Viral; D005260:Female; D006561:Herpes Simplex / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology*; D018259:Herpesvirus 1, Human / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000821:virology*; D013280:Stomatitis / Q000188:drug therapy / Q000821:virology; D017201:Virus Shedding
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir